HerbParlor
Boswellia (Boswellia serrata Roxb.)Emerging evidence

Boswellia

Boswellia serrata Roxb.

Overview

At a glance

Boswellia is the gum resin of Boswellia serrata Roxb., a Burseraceae botanical with a long Ayurvedic and South Asian history. Human research has focused particularly on osteoarthritis symptoms, with findings that vary by preparation and standardized extract.

Key takeaway

Boswellia is not one uniform intervention. Species identity, resin material, powder or extract preparation, standardization and the outcome studied all matter. Some studies report improvements in osteoarthritis pain or function, but evidence for one named extract must not automatically be generalized to other Boswellia products, and overall high-quality evidence remains limited.

Common uses studied

Ayurvedic and South Asian traditional-medicine contextBoswellia gum resin and resin powder productsStandardized extract researchOsteoarthritis pain and function researchCommercial joint-health products

Start here

What are you trying to figure out?

Pick the question closest to yours. Each card jumps to the relevant part of this profile or an existing HerbParlor tool — no sponsored rankings, no hidden ordering.

Understand the herbExplore the evidenceUnderstand formsCheck safetyEvaluate a supplementCompare options

Identity

What is this herb?

Family

Burseraceae

Species

Boswellia serrata Roxb.

Common names

BoswelliaIndian frankincenseShallaki

Plant parts used

Gum resin / resin

Geographic context

Boswellia serrata is a South Asian tree associated with resin production and traditional use in the Indian subcontinent. Geographic and botanical claims should be limited to what is supported by the cited source.

Identification notes

This profile refers to Boswellia serrata Roxb. and its gum resin. Boswellia is a genus containing multiple species, so a label that says only “Boswellia” does not by itself establish species identity. Resin, powder and extracts should not be treated as equivalent without clear product information.

Background

Traditional context

Traditions

Ayurvedic medicineSouth Asian traditional-medicine contexts

Historical uses

Traditional use of Boswellia gum resin preparationsHistorical use in Ayurvedic and South Asian herbal-medicine frameworks

Traditional use is historical and cultural context, not proof of efficacy. Modern clinical conclusions should be based on human research involving the specific Boswellia species, preparation, standardized extract and outcome studied.

Preparations

Forms & preparations

Forms

Raw or dried gum resinResin powderGum-resin extractStandardized Boswellia extractCapsuleTabletLiquid preparationCombination formula

Preparation methods

Dried resin materialPowdered resinSolvent or other extract preparationStandardized extract preparation where explicitly disclosedLiquid preparation or tincture where explicitly disclosed

What changes between forms

  • Gum resin, resin powder, extract and standardized extract are different preparations and are not automatically interchangeable.
  • A named standardized extract studied in a trial is not automatically equivalent to ordinary resin powder, another extract or every commercial Boswellia product.
  • Species identity, extraction method, resin composition and standardization can change what evidence applies.
  • Combination products should not automatically be treated as evidence for Boswellia alone.
  • Capsules, tablets and liquids may contain different preparations and amounts of resin or extract.

Human studies have used specific Boswellia resin or standardized-extract preparations. Findings should be interpreted at the level of the studied product or extract and should not be generalized automatically to all Boswellia forms.

Research

Research Explorer

Each question summarizes what human research has examined, how it was studied, and the main limitations — not a treatment recommendation.

What does human evidence show about Boswellia and osteoarthritis symptoms?

Population

Adults with osteoarthritis represented in randomized trials and systematic reviews of Boswellia resin or Boswellia extracts.

Intervention

Boswellia serrata resin or named standardized Boswellia extracts as described in the relevant studies.

Comparator

Placebo or comparator interventions where used.

Outcomes studied

PainPhysical functionStiffnessPatient-reported symptomsAdverse events

Evidence assessment

Some studies and meta-analyses report improvements in osteoarthritis pain, function or related symptoms. The findings are limited by variation in preparations, standardized extracts, sample sizes, study quality, outcome measures and follow-up. These results do not establish Boswellia as a proven treatment and do not justify a dosage recommendation.

Limitations

  • Variation in resin and extract preparations
  • Differences in standardization and product identity
  • Small or limited clinical studies and variable methodological quality
  • Differences in pain, function and structural outcomes
  • Findings should not be generalized to every commercial Boswellia product

Sources

How much does the preparation affect interpretation of Boswellia evidence?

Population

People comparing commercial Boswellia products with the preparations studied in human research.

Intervention

Gum resin, resin powder, extracts and named standardized Boswellia preparations.

Comparator

Not applicable.

Outcomes studied

Preparation identityStandardizationEvidence interpretability

Evidence assessment

Evidence varies by preparation and standardized extract. A result for one named extract must not automatically be generalized to a different extract, resin powder, combination product or unidentified Boswellia product. Preparation identity is part of the intervention, not a minor label detail.

Limitations

  • Commercial labels may omit extract identity or standardization
  • Studies do not use one uniform Boswellia intervention
  • Extract compositions and reported marker amounts may not be comparable

Sources

How strong and consistent is the overall human evidence?

Population

Individuals represented across the available Boswellia human clinical literature.

Intervention

Boswellia serrata resin and extract preparations studied in humans.

Comparator

Varies by study and review.

Outcomes studied

Osteoarthritis painPhysical functionJoint symptomsCartilage or structural measuresAdverse events

Evidence assessment

Human research has focused particularly on osteoarthritis symptoms, and some studies report improvements in pain or function. Overall high-quality evidence remains limited, with uncertainty about preparation, standardization, study quality, clinical importance and generalizability. The evidence does not establish broad joint-health, anti-inflammatory or disease-modifying claims.

Limitations

  • Limited number and size of high-quality studies
  • Preparation and standardized-extract heterogeneity
  • Uncertain clinical relevance of some structural or biomarker outcomes
  • Insufficient basis for broad claims beyond the studied outcomes

Sources

Latest evidence

Recently published research

Searching Europe PMC…

Looking for recent publications…

These publications are automatically discovered from Europe PMC. They have not necessarily been independently reviewed by HerbParlor and are not automatically incorporated into the evidence assessment.

Evidence

Evidence

Human research on Boswellia has focused particularly on osteoarthritis symptoms. Some studies and meta-analyses report improvements in pain, function or related symptoms, but findings vary by preparation and standardized extract and are limited by study quality, sample size, follow-up and outcome differences. Overall high-quality evidence remains limited. Evidence for one named extract must not automatically be generalized to other Boswellia products, and the available evidence does not establish Boswellia as a proven treatment for osteoarthritis or other diseases.

Evidence tier

Emerging

Confidence

Overall confidence is emerging rather than established. The main uncertainties concern species identity, resin or extract preparation, standardization, amount, duration, study quality, clinical importance and whether a commercial product matches the intervention studied.

Last evidence review

2026-09-20

Where the evidence is strongest

Human osteoarthritis research addressing pain and physical functionPreparation-aware synthesis that distinguishes resin, powder, extracts and named standardized extracts

How to interpret this

The evidence does not establish that Boswellia prevents or cures osteoarthritis, regenerates cartilage, treats every form of joint pain, provides a universal anti-inflammatory effect, or is equivalent across products and preparations. It also does not establish a dosage recommendation, long-term safety for every product, or efficacy for conditions not studied in the relevant human research.

Automatic evidence update

Since the last editorial review

Checking Europe PMC…
Checking evidence

Checking for publications published since the last editorial evidence review…

This automatic update detects newly published literature; it does not replace HerbParlor's editorial evidence assessment. Review status is an automatic triage signal. Curated HerbParlor evidence is unchanged until editorial review.

Boundaries

What the evidence does NOT establish

Areas with limited evidence

  • Claims that Boswellia broadly treats joint disease or inflammation
  • Generalization from one named extract to every Boswellia product
  • Claims of cartilage regeneration or disease modification based on limited structural findings
  • Clinical conclusions from traditional use, laboratory findings or biomarkers alone

Evidence gaps

  • Larger, longer and well-described randomized trials with independent confirmation
  • Direct comparisons of resin, powder, extracts and standardized extracts
  • Consistent reporting of species, preparation, standardization, amount and product identity
  • Clinically meaningful outcomes and better assessment of long-term safety

Common misconceptions

  • Traditional Ayurvedic use is historical context, not proof of efficacy.
  • Boswellia resin powder is not automatically equivalent to a standardized extract.
  • A study of one named extract does not validate every Boswellia product.
  • An improvement in pain or function does not establish cartilage regeneration or disease modification.
  • Laboratory, mechanistic or biomarker findings are not the same as clinical benefit.
  • A Boswellia-containing combination formula does not provide the same evidence as Boswellia alone.
  • More resin or extract does not automatically mean better evidence.

Safety

Safety & interactions

General considerations

  • Safety should be interpreted according to the specific Boswellia preparation, amount and duration studied; resin, powder and concentrated extracts are not automatically equivalent.
  • NCCIH describes gastrointestinal symptoms such as nausea, acid reflux, diarrhea or abdominal discomfort as possible adverse effects; the available sources do not establish a complete safety profile for every product.
  • Product composition and standardization can vary, so safety findings from one named extract should not automatically be applied to every Boswellia product.
  • Oral products should be distinguished from topical or other preparations, which are not automatically interchangeable.

Pregnancy & nursing

  • Pregnancy and breastfeeding safety information is limited; safety should not be assumed for every Boswellia preparation, particularly concentrated extracts.
  • People who are pregnant or breastfeeding should discuss a specific product with a qualified healthcare professional.

Medication interactions to be aware of

Interaction information is incomplete for the range of Boswellia preparations sold commercially. People taking medicines should discuss a specific product with a qualified healthcare professional rather than infer safety from traditional use.

Condition considerations

  • People with gastrointestinal, liver, autoimmune or other medical conditions should not use this profile as a substitute for clinical care.
  • Uncertainty is greater when a product does not identify its species, plant part, preparation, standardization or amount.

Reported adverse effects

  • Nausea
  • Acid reflux
  • Diarrhea
  • Abdominal discomfort

Duration

  • Long-term safety of concentrated Boswellia extracts is not equally established for every commercial product.

Talk to a healthcare professional if any apply

  • Pregnancy or breastfeeding
  • Use of prescription medicines
  • Gastrointestinal, liver, autoimmune or other relevant medical conditions
  • Use of a concentrated or standardized extract with unclear composition
  • Significant or unexpected adverse effects

Products

What changes between products?

Form differences

  • Gum resin, resin powder, extract and standardized extract are different preparations and are not automatically interchangeable.
  • A named standardized extract studied in a trial is not automatically equivalent to ordinary resin powder, another extract or every commercial Boswellia product.
  • Species identity, extraction method, resin composition and standardization can change what evidence applies.
  • Combination products should not automatically be treated as evidence for Boswellia alone.
  • Capsules, tablets and liquids may contain different preparations and amounts of resin or extract.

Form considerations

  • Resin, resin powder, extract and standardized extract can represent different preparations and should not be compared solely by headline milligrams.
  • A product listing a named extract should be assessed for whether the same extract was used in the cited human research.

Plant part considerations

  • Confirm that the product uses identified Boswellia gum resin when that is the intended preparation.
  • Do not treat another plant part or another Boswellia species as automatically equivalent.

Extract considerations

  • Record extract identity, extraction method and ratio only when the product source explicitly provides them.
  • Do not infer clinical equivalence, concentration or efficacy from an unspecified extract amount.

Standardization considerations

  • Record declared standardization only when genuinely disclosed and sourceable.
  • Do not invent a boswellic-acid threshold or imply that standardization automatically means greater efficacy.

Evaluation

How to evaluate a supplement

What to check

  • Boswellia species identity, especially Boswellia serrata Roxb. where that is the intended material
  • Gum resin / resin plant part
  • Whole resin or powder versus extract
  • Standardized extract identity and declared standardization where genuinely disclosed
  • Amount per serving and serving information
  • Extraction information and marker compounds only where explicitly specified
  • Whether the product is Boswellia alone or a combination formula
  • Other ingredients and label transparency
  • Identity, contaminant and batch or lot testing where disclosed

Serving considerations

  • Compare the labelled preparation and amount with the intervention used in the relevant research without inventing a dosage recommendation.
  • A larger declared amount does not automatically mean a stronger or better-supported product.

Testing considerations

  • Look for species and resin identity testing where disclosed.
  • Look for contaminant testing and batch or lot traceability where disclosed.
  • Treat testing and standardization information as product-quality disclosure, not proof of clinical efficacy.

Label transparency

  • The species and plant part should be clear where possible.
  • Resin, powder, extract and standardized-extract details should be explicit.
  • The labelled amount and serving should be explicit.
  • Combination ingredients should be listed.
  • Marketing language should not be treated as human clinical evidence.

Supplements

Related supplements

Sources

Authoritative sources referenced

research-reviewedLast reviewed 2026-09-20Next review 2027-09-20

Sections reviewed

overviewbotanicaltraditionalContextpreparationsresearchevidencesafetyproductEvaluationrelationshipssources

Created the Boswellia Herb Profile v1 with Boswellia serrata Roxb. gum resin as the canonical herbal material, Ayurvedic and South Asian historical context, preparation-aware osteoarthritis evidence, cautious safety framing, explicit evidence limitations, product-evaluation criteria and auditable review metadata.

Regulatory sources are included for context only. Regulatory status is not evidence for or against efficacy, and is not a treatment or safety recommendation.

This profile is provided for educational purposes only and is not medical advice. Traditional context and research summaries are distinguished from claims, and nothing here is a treatment recommendation. Always consult a qualified healthcare professional before using any herb, especially if you are pregnant, nursing, take medication, or have a medical condition.